Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy

被引:3
|
作者
Huang, Chih-Wen [1 ]
Yang, Chen-Ta [1 ]
Su, Pei-Yuan [1 ,2 ]
Chen, Yang-Yuan [1 ,2 ]
Huang, Siou-Ping [1 ]
Yen, Hsu-Heng [1 ,2 ]
机构
[1] Changhua Christian Hosp, Dept Internal Med, Div Gastroenterol, Changhua 500, Taiwan
[2] Natl Chung Hsing Univ, Coll Med, Taichung 400, Taiwan
关键词
chronic hepatitis B; entecavir; tenofovir alafenamide; finite therapy; clinical relapse; HBEAG-NEGATIVE PATIENTS; DISOPROXIL FUMARATE; SURFACE-ANTIGEN; SAFETY;
D O I
10.3390/biomedicines11030752
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic hepatitis B (CHB) relapse occurs after the cessation of nucleos(t)ide analogues (NUC) therapy due to the waning of viral suppression. Few studies have investigated the viral relapse rate and clinical relapse rate after tenofovir alafenamide (TAF) therapy. We compared the CHB relapse rate between TAF and entecavir therapy. We enrolled patients with chronic hepatitis B who underwent TAF or entecavir therapy. NUC therapy was terminated after HBeAg loss for 1 year in HBeAg-positive patients and after undetectable serum HBV DNA on three separate tests each >6 months apart in HBeAg-negative patients. After cessation of NUC therapy, we followed alanine aminotransferase (ALT) levels at 12, 24, and 48 weeks. Serum HBV DNA levels were checked if patients showed a two-fold elevation from the upper limit of normal ALT levels (41 IU/mL). Clinical relapse (CR) was defined as a two-fold elevation in ALT levels and HBV DNA levels > 2000 IU/mL. We then investigated the CR rate of HBV after cessation of TAF and entecavir therapy at 12, 24, and 48 weeks. Of the 117 patients enrolled, 78 were in the entecavir group and 39 were in the TAF group. At 12 weeks after cessation of NUC therapy, no patients had HBV CR in the entecavir group. However, three patients (CR cumulative rate 7.9%) had CR in the TAF group. At 24 weeks, the CR cumulative rate in the entecavir and TAF groups were 1.3% and 13.2%, respectively (p < 0.05). At 48 weeks, the CR cumulative rates were 9.2% and 24.2%, respectively (p = 0.055). Patients in the TAF group had a higher cumulative rate of CR than those in the entecavir group (log-rank p = 0.023). Furthermore, patients in the TAF group had earlier CR times than those in the entecavir group, especially in the first 24 weeks after cessation of therapies (p < 0.05). The cessation of TAF therapy had significantly earlier and higher CR rates than that of entecavir therapy. Close monitoring of liver function and HBV DNA levels may be necessary, especially within 24 weeks after cessation of TAF therapy.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients
    Huang, Rui
    Yao, Renling
    Wu, Weihua
    Wang, Jian
    Wu, Chao
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (08) : 1105 - 1106
  • [2] Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy
    Fang, Hsin-Wei
    Tseng, Po-Lin
    Hu, Tsung-Hui
    Wang, Jing-Houng
    Hung, Chao-Hung
    Lu, Sheng-Nan
    Chen, Chien-Hung
    VIROLOGY JOURNAL, 2024, 21 (01)
  • [3] Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy
    Hsin-Wei Fang
    Po-Lin Tseng
    Tsung-Hui Hu
    Jing-Houng Wang
    Chao-Hung Hung
    Sheng-Nan Lu
    Chien-Hung Chen
    Virology Journal, 21
  • [4] Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B
    Hagiwara, Satoru .
    Nishida, Naoshi
    Ida, Hiroshi
    Ueshima, Kazuomi
    Minami, Yasunori
    Takita, Masahiro
    Komeda, Yoriaki
    Kudo, Masatoshi
    JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (10) : 1804 - 1810
  • [5] Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
    Itokawa, Norio
    Atsukawa, Masanori
    Tsubota, Akihito
    Takaguchi, Koichi
    Nakamuta, Makoto
    Hiraoka, Atsushi
    Kato, Keizo
    Abe, Hiroshi
    Mikami, Shigeru
    Shimada, Noritomo
    Chuma, Makoto
    Akito, Nozaki
    Uojima, Haruki
    Ogawa, Chikara
    Asano, Toru
    Tani, Joji
    Morishita, Asahiro
    Senoh, Tomonori
    Yamashita, Naoki
    Oikawa, Tsunekazu
    Matsumoto, Yoshihiro
    Koeda, Mai
    Yoshida, Yuji
    Tanabe, Tomohide
    Okubo, Tomomi
    Arai, Taeang
    Hayama, Korenobu
    Iwashita, Ai-Nakagawa
    Kondo, Chisa
    Tada, Toshifumi
    Toyoda, Hidenori
    Kumada, Takashi
    Iwakiri, Katsuhiko
    JGH OPEN, 2021, 5 (01): : 34 - 40
  • [6] Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B
    Tamaki, Nobuharu
    Kurosaki, Masayuki
    Nakanishi, Hiroyuki
    Itakura, Jun
    Inada, Kento
    Kirino, Sakura
    Yamashita, Koji
    Osawa, Leona
    Sekiguchi, Shuhei
    Hayakawa, Yuka
    Wang, Wan
    Okada, Mao
    Higuchi, Mayu
    Takaura, Kenta
    Maeyashiki, Chiaki
    Kaneko, Shun
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Takahashi, Yuka
    Izumi, Namiki
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (08) : 1355 - 1358
  • [7] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE AFTER SWITCHING FROM ENTECAVIR IN PATIENTS WITH CHRONIC HEPATITIS B
    Hann, Hie-Won L.
    Park, Grace
    Bin Park, Kyong
    Juon, Hee-Soon
    HEPATOLOGY, 2021, 74 : 480A - 480A
  • [8] Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg-Negative Chronic Hepatitis B
    Tseng, Cheng-Hao
    Lee, Teng-Yu
    Chen, Chi-Yi
    Huang, Chung-Feng
    Chen, Po-Yueh
    Jang, Tyng-Yuan
    Yang, Tzeng-Huey
    Wu, Chia-Ching
    Hsu, Yao-Chun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025,
  • [9] The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients
    Chen, C-H
    Hsu, Y-C
    Lu, S-N
    Hung, C-H
    Wang, J-H
    Lee, C-M
    Hu, T-H
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 (05) : 590 - 597
  • [10] Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir
    Kuo, Ming-Te
    Hu, Tsung-Hui
    Hung, Chao-Hung
    Wang, Jing-Houng
    Lu, Sheng-Nan
    Tsai, Kai-Lung
    Chen, Chien-Hung
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (02) : 218 - 228